- BeiGene, a Chinese developer of drugs that target a body’s immune system to fight cancer. With a team of more than 215 scientists and other staff members, it is creating a pipeline of oral drugs and antibodies to treat cancer.
- There were 84 biotech companies that went public in the United States in 2014, the largest number on record, while last year 50 such companies conducted IPOs, according to Dealogic.
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiGpGruCcQUcTJH_Za7GLcHsQaw2cBKWAqiKwRlwj6Wf_Wg_VzQ_nSMmOYQ6TgVpfoF8rOzi6977BR3LZi09HfXSR4GO4DpAima4ZG8f4dphB0m6h3bo7HbwTjEtgsmy6J-2e-5up5nNvU/s1600/BGNE.png)
BeiGene (NASDAQ: BGNE) opened for trading at $28.97 after pricing of its initial public offering of 6,600,000 American Depositary Shares (ADS), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS.
Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers. Baird is acting as co-manager of the offering.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
No comments:
Post a Comment